Resistant maltodextrin (RMD) is a soluble dietary fiber ingredient whose physiological functions are well recognized in Foods for Specified Health Use (FOSHU) for maintaining healthy intestinal regularity, blood glucose levels, and serum lipids. However, its efficacy on combined health risks-metabolic syndrome-was not studied yet. In this study the efficacy of RMD on humans with metabolic syndrome was investigated. A randomized double-blind placebo-controlled parallel-group trial was conducted. Thirty subjects with metabolic syndrome were randomly allocated into 2 groups and took either tea containing 9 g of RMD (treatment group) or placebo tea at three mealtimes daily for 12 wk. Blood was collected and body fat was scanned periodically. In the RMD treatment group, waist circumference, visceral fat area, fasting blood glucose, HOMA-R and serum triacylglycerol (TG) were significantly decreased compared to baseline, and significant time-by-treatment interaction was observed for waist circumference, visceral fat area, HOMA-R and serum TG (p50.044, p50.012, p50.032, and p50.049, respectively) . The change ratio of visceral fat area showed negative statistical correlation with the baseline value (p50.033), suggesting that efficacy of RMD was emphasized in the subjects having a larger visceral fat area. After the 12-wk RMD treatment, the total number of metabolic syndrome risk factors decreased to 20 from 32 with 2 subjects having no risks, while that of the placebo group decreased to 25 from 32. These findings suggest that continuous ingestion of RMD may improve the risk factors of metabolic syndrome by reducing visceral fat and improving glucose and lipid metabolism.
The term "metabolic syndrome" indicates a body condition having more than a doubled risk of sudden death from ischemic heart disease or stroke compared to healthy people. In metabolic syndrome, dyslipidemia, impaired glucose tolerance and hypertension are complexly developed with underlying visceral fat accumulation, which is considered to be the primary abnormal condition (1) .
Over the years metabolic syndrome has been called by various names, such as syndrome X (2), deadly quartet (3), visceral fat syndrome (4), etc.; however, recently the term metabolic syndrome has been used as the standard name around the world. World Health Organization, International Diabetes Federation, National Cholesterol Education Program's Adult Treatment Panel III and many other organizations have established their own diagnostic criteria (5, 6) . In Japan diagnostic criteria for Japanese were also established in 2005 considering racial differences, in which visceral fat accumulation is necessary as the primary risk factor, and then 2 or more additional risk factors are required from the following; 1) dyslipidemia, 2) hypertension and 3) hyperglycemia (7) . On this basis, it is reported that about 25% of male adults meets the criteria of metabolic syndrome in Japan (8) .
In Japan ischemic heart disease and cerebrovascular disease are the second and third causes of mortality while cancer is the leading cause (9) . The improvement and prevention of metabolic syndrome are very important for public health, because metabolic syndrome increases the incidence of sudden death from ischemic heart disease and cerebrovascular disease.
Visceral fat accumulation is the primary risk factor of metabolic syndrome, and reduction of visceral fat is expected to improve dyslipidemia, impaired glucose tolerance and hypertension. Hence, the management of visceral fat accumulation is considered the most important to reduce the risk of metabolic syndrome. Improvement of dietary habits and continuous exercise are the top priority in the strategy to reduce visceral fat accumulation (10, 11) ; however, it is generally difficult to sustain these efforts over a long time, and eventually dropout is often the case (12) (13) (14) . Effective dietary therapy and exercise therapy designed to be able to be continued over a long time are desired to prevent the expansion of metabolic syndrome.
Brown et al. indicated in their meta-analysis report that dietary fiber may play an important role in the treatment of obesity (15) . Additionally, as the result of epidemiological surveys a possibility was indicated that high consumption of dietary fiber may delay the development of diabetes and prevent coronary heart disease (16, 17) . Particularly, soluble dietary fiber has been reported to reduce coronary heart disease by improving insulin resistance, postprandial glucose levels and dyslipidemia (18, 19) . These results suggest that the consumption of dietary fiber may improve the accumulation of visceral fat and prevent the development of metabolic syndrome.
Resistant maltodextrin (RMD) is a non-viscous soluble dietary fiber having various physiological effects, which were demonstrated by in-vitro, in-vivo and clinical experiments (20) (21) (22) (23) . It has been reported that the continuous ingestion of 15-30 g/d of RMD significantly improves glucose and lipid metabolism (24) (25) (26) . However, such physiological effects have not been evaluated in subjects who have multiple health risks such as metabolic syndrome, but for single purposes, i.e., improvement of intestinal regularity only, glucose metabolism only, etc.
We previously reported that continuous 12-wk ingestion of tea containing RMD decreased serum triacylglycerol (TG) and visceral fat accumulation in humans (27) .
The inclusion criterion to screen subjects was to have a body mass index (BMI) equal to 23 or more; however, it was found that there was a sufficient number of subjects for statistical analysis when metabolic syndrome was adopted as the inclusion criterion. Therefore, we conducted a re-evaluation of the data to clarify the effect of RMD in humans with combined health risks-metabolic syndrome.
ExpERIMEntAl
Screening of subjects. In conducting this clinical study, the protocol was approved in advance by the ethical review board of Isozaki Clinic, where the clinical study was conducted. In accordance with the spirit of the Helsinki Declaration of 2004, participants were provided with a thorough explanation of the experimental objectives, content, methods, anticipated adverse effects and other such information in advance, and their voluntary informed consent to experimental participation was obtained in writing.
A total of 38 mildly-obese subjects (23 males and 15 females) was screened according to the Japanese diagnostic criteria of metabolic syndrome as follows: firstly to exhibit visceral fat obesity (to have a waist circumference greater than or equal to 85 cm for men and 90 cm for women, which corresponds to a visceral fat area equal to 100 cm 2 or larger, and is diagnosed as visceral fat obesity), and next to satisfy two out of three of the following: 1) dyslipidemia (to have serum TG equal to 150 mg/dL (1.7 mmol/L) or higher and/ or to have serum HDL-cholesterol less than 40 mg/dL (1.03 mmol/L)), 2) impaired glucose tolerance but not diabetes (to have fasting blood glucose of 110-126 mg/ dL (6.1-7.0 mmol/L)), or 3) high blood pressure equal to 130/85 mmHg or higher. Exclusion criteria were diabetes and medical treatment with fibrates, thiazolidines or anion-exchange resins.
Outline of the study. An unsweetened blended tea drink containing 9 g (as the dietary fiber amount) of RMD (Fibersol ® -2, Matsutani Chemical Industry Co., Ltd., Hyogo, Japan) in a 280-mL bottle was prepared as the test drink. A placebo tea drink was also prepared in the same bottle without RMD, which was not distinguishable from the test drink in taste or appearance. The ingredients other than RMD were oolong tea, Job's tears tea and vitamin C, and the nutrient content of the test and placebo teas was the same except for the dietary fiber amount (9 g/serving for the test drink and 0 g for the placebo) and energy value from RMD (74.9 kJ517.9 kcal/serving for the test drink and 0.0 kJ for the placebo). Subjects consumed 3 bottles of the test or placebo drink daily, 1 bottle at each mealtime over 12 wk.
The study was designed as a randomized, doubleblind, placebo-controlled parallel-group trial with a 12-wk intervention period. Subjects were randomly allocated into either the treatment group or the placebo group.
The measurements of body weight, waist circumference and blood pressure, the collection of fasting blood, and the interview for diet survey by a registered dietitian were carried out at week 0 (baseline), 4, 8 and 12. Waist circumference was measured accurately by skilled technicians. Abdominal CT scans were conducted at weeks 0 and 12.
The subjects were instructed not to change their lifestyle, including diet, exercise and medication, during the intervention period.
From the diet record of five consecutive days, intake of fat, protein, carbohydrate and dietary fiber were analyzed using nutrition analysis software (RakuRaku Eiyo Sodan EX, Yumekobo, Inc., Hyogo, Japan). Exercise amount for the same 5 d was evaluated using a pedometer (HJ-710IT, Omron Healthcare, Kyoto, Japan). Fasting body weight was measured after micturition, and umbilicus circumference was measured for waist circumference. Blood pressure was measured in a sitting position using an automated blood pressure measurement device (Intelligent Sensing, Omron, Kyoto, Japan).
Serum TG, VLDL-TG, LDL-TG, total cholesterol, HDL cholesterol, LDL cholesterol, blood glucose, insulin, adiponectin and leptin were the parameters to be analyzed from blood samples. Analysis of blood was entrusted to a clinical laboratory organization, SRL, Inc. (Tokyo, Japan), which used standardized analytical methods. HOMA-R was calculated as the index for insulin resistance (HOMA-R5fasting plasma insulin [mU/L]3fasting plasma glucose [mmol/L]/22.5).
Visceral fat area was measured by abdominal CT scan (Asteion TSX-021B, Toshiba Medical Systems, Tochigi, Japan) with the software Fat Scan (N2 System Co., Ltd., Osaka, Japan) based on the CT measurement method of Tokunaga et al. (28) .
Statistical analysis. Data are expressed as mean6SD. Time-by-treatment interaction was assessed by repeatedmeasures ANOVA. For the comparison within a group, the paired t-test and Dunnett's multiple comparison test were employed. The t-test was used for the comparison between groups. For visceral fat areas, analysis of covariance (ANCOVA) was conducted for the percent change after 12 wk, using the baseline value as the covariate. The correlation in visceral fat areas was calculated using Pearson's correlation coefficient.
SPSS Ver 15.0 (SPSS Japan Inc., Tokyo, Japan) was used for data analysis. The significant level was set at p,0.05 (two-tailed test).
RESultS
There were 30 subjects (20 males and 10 females) with metabolic syndrome, 15 subjects (11 males and 4 females) in the placebo group and 15 (9 males and 6 females) in the treatment group, as the result of screening baseline characteristics of the subjects by the Japanese diagnostic criteria for metabolic syndrome. No significant differences were found in baseline characteristics between the placebo group and the treatment group (Table 1) .
Changes in body weight, BMI, and waist circumference are shown in Table 2 . Significant time-by-treat- Values are expressed as mean6SD. p-value was assessed by t-test. Table 3 . Significant time-by-treatment interaction was observed in the visceral fat area (p50.012), which decreased significantly in the treatment group at week 12 (p,0.01) compared to baseline and also to the placebo group at the same time-point (p,0.05). Accordingly, the total fat area also decreased significantly at week 12 compared to baseline (p,0.05). No significant changes in the subcutaneous fat area were observed. By plotting the change ratio of the visceral fat area on the vertical axis with the baseline visceral fat on the horizontal axis, a significant negative correlation was observed in the treatment group (Fig. 1, r520.551, p50 .033), indicating that RMD treatment had a greater impact on the subjects who had larger visceral fat areas at baseline. Figure 2 illustrates a representative CT image of a subject in the treatment group, who showed a remarkable decrease in visceral fat.
Changes in fasting blood glucose, fasting insulin and HOMA-R are shown in Table 4 . Fasting blood glucose decreased significantly in the treatment group at week 8 and week 12 (p,0.01 for each time-point) compared to baseline. Fasting insulin did not change significantly, but Values are expressed as mean6SD. p-value for time-by-treatment interaction was assessed by repeated measure ANOVA. Significant difference from baseline was assessed by paired t-test and marked as # p,0.05 and ## p,0.01. Significant difference by treatment was assessed by ANCOVA using baseline value as covariate and marked as * p,0.05. HOMA-R, an index of insulin resistance, decreased significantly in the treatment group at week 8 and week 12 (p,0.01 for each time-point) compared to baseline, and a significant time-by-treatment interaction (p50.032) was observed.
Changes in blood lipids are shown in Table 5 . Significant time-by-treatment interaction was observed in serum TG (p50.049), decreasing significantly in the treatment group at week 8 and week 12 (p,0.01 each) compared to baseline, and also to the placebo group at week 12 (p,0.05). Significant changes in VLDL-TG were observed in the treatment group at week 8 and week 12 (p,0.01 each) compared to baseline and also to the placebo group at week 12 (p,0.05). For LDL-TG significant changes were observed in the treatment group at week 8 and week 12 (p,0.01 each) compared to baseline with a statistical trend in time-by-treatment interaction (p50.087). Total cholesterol fell significantly in the treatment group at week 12 compared to baseline (p,0.05). No significant changes were observed in LDLcholesterol or HDL-cholesterol.
In the treatment group, there was a significant increase in adiponectin at week 12 compared to baseline (p,0.05), but not in leptin (Table 6 ).
No significant changes were observed in systolic blood pressure, diastolic blood pressure, total energy intake, dietary fiber intake from meals, or foot step counts (data not shown).
Subjective abdominal symptoms were reported by 5 subjects (flatus in 5 subjects and abdominal sound in 1 subject) in the treatment group and 1 subject (flatus) in the placebo group. Diarrhea was reported by 1 subject in each group. All of these symptoms were transient and did not cause discontinuation of the intervention in any of the subjects.
DISCuSSIon
The previous study in mildly-obese subjects confirmed that the ingestion of RMD effectively decreased visceral fat and serum TG (27) . From the result, it was expected that RMD would also be effective to manage the risk factors of metabolic syndrome; however, it was not confirmed since the diagnostic criteria for metabolic syndrome were not adopted at the screening of subjects.
In the present study, we limited the data on the subjects with metabolic syndrome, and found that the continuous ingestion of RMD significantly decreased their visceral fat area and fasting serum TG with significant timeby-treatment interaction; these values of the treatment group were significantly lower at week 12 than those at baseline and also lower than that of the placebo group at the same time-point. For visceral fat area, significant negative correlation was found in the treatment group between the baseline value and the change ratio, suggesting that the efficacy of RMD is more remarkable on the subjects who have more visceral fat. These findings are consistent with the previous report. In this study, the gender allocation was not exactly even in the groups and the possibility that gender difference might affect the result is not negligible in a small study. Body fat is particularly likely to reflect gender difference, so we did a gender analysis in the treatment group on visceral fat area, which was significantly decreased. The change rate in visceral fat area by gender was very similar between males (218.8615.2%) and females (218.0621.2%), suggesting that the difference in gender ratio did not affect the result. Measurement of waist circumference is an indirect but conveniently-used supporting index of visceral fat accumulation. In the current study with metabolic syndrome subjects, a significant reduction in waist circumference was newly shown in the RMD treatment group at week 8 and week 12 with a significant time-by-treatment interaction.
Additionally, fasting blood glucose and HOMA-R were significantly decreased by the treatment with RMD in the current analysis, which suggests that the continuous ingestion of RMD is effective not only to decrease visceral fat area and fasting TG, but also to improve fasting blood glucose and insulin resistance in subjects with metabolic syndrome.
High fasting TG and high fasting blood glucose are used as the secondary diagnostic criteria along with high blood pressure. Abnormal values in fasting TG, fasting blood glucose and blood pressure are counted as metabolic syndrome risk factors. As a specific result on metabolic syndrome, the total number of metabolic syndrome risk factors of the group other than visceral fat obesity was decreased to 20 from 32 by the 12-wk treat- Values are expressed as mean6SD. p-value for time-by-treatment interaction was assessed by repeated measure ANOVA. Significant difference from baseline was assessed by Dunnett and marked as # p,0.05. Significant difference by treatment was assessed by t-test. ment with RMD, resulting in no risk factors in 2 subjects at the end. The number of risk factors for the placebo group was also decreased to 25 from 32, which would be considered as an intervention effect. While no significant changes were found in energy intake, dietary fiber intake, or exercise amount, for either group, it is considered that the professional interview on meals, exercise, etc. and body measurements conducted every 4 wk somewhat affected their lifestyles. The slight differences in energy intake and exercise amount between the RMD group and the placebo group found in Table 1 might have affected the results favorably for the RMD group; however, considering that there was the additional energy intake from the RMD beverage (225 kJ/d553.7 kcal/d), the possibility is very low.
As shown in Table 6 , adiponectin was changed by the 12-wk treatment with RMD, but leptin was not. Adiponectin is known to negatively associate with visceral fat area, and leptin is known to correlate with body fat, but more strongly with subcutaneous fat area (29) (30) (31) (32) . These reports correspond well to the result of this study that a significant decrease was found in visceral fat area with an increase in adiponectin, but not in subcutaneous fat area or leptin. The increase in adiponectin and improvement in HOMA-R by RMD treatment are also consistent with the published data showing adiponectin is associated with insulin sensitivity (29, 31) .
The favorable effect on body fat accumulation, serum TG and glucose metabolism by continuous ingestion of RMD is considered a result of the effect of RMD on digestion and absorption of sugar and fat from meals. Many reports by Japanese researchers state that RMD moderates the absorption of sugar and attenuates postprandial rises in blood glucose and insulin. A systematic review with the use of meta-analysis was also conducted on these reports to ensure the consistency and reliability of the data (21) . Further in recent studies, RMD was found to suppress absorption of fat and attenuate postprandial rises in TG and insulin (23, 33) . A postprandial insulin spike is known to promote lipogenesis, leading the accumulation of visceral fat. The reduction of visceral fat shown in this study would be well explained if the continuous ingestion of RMD suppressed excessive postprandial insulin secretion, which accompanies lipogenesis.
Resistant maltodextrin (RMD) is a non-viscous palatable water-soluble dietary fiber ingredient. Already found in numerous FOSHU (Foods for Specified Health Use, the Japanese regulatory system for health claims on foods) products as an effective key ingredient, RMD is readily formulated not only into beverages but also into various foods, and is therefore considered to be suitable for dietary treatment over a long time. The continuous administration of RMD is expected as a useful and promising strategy for the treatment of obesity and improvement of metabolic syndrome.
